BioAge Labs

What it is

BioAge Labs is a public clinical-stage biotech that built its discovery platform on longitudinal aging cohorts — analysing how human plasma biomarkers change over decades and which patterns predict longevity vs early decline.

Lead programmes

• Azelaprag (BGE-105) — an apelin-receptor agonist for obesity, in trials to potentiate GLP-1 effects and preserve lean mass during weight loss.
• BGE-117 — HIF stabiliser for muscle and metabolic indications.

What happened

In late 2024 BioAge halted the lead azelaprag obesity programme due to unexpected liver-enzyme elevations in trial participants. The company pivoted to other indications; the share price fell substantially.

Why it still matters

BioAge’s platform thesis — that longitudinal aging-cohort data can nominate druggable targets that conventional drug-discovery misses — remains intact even if the lead candidate failed. The general data-driven approach is shared by an increasing number of companies.

Related entries

Pace of aging, GLP-1 agonists, Sarcopenia.